33148-82-2

Upstream product

• 4066-41-5 5-acetylthiophene-2-carboxylic acid 
• 64-17-5 ethanol 

Downstream Products

• 223499-20-5 5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-thiophene-2-carboxylic acid 
• 175202-29-6 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)thiophene-2-carboxylic acid 
• 947540-58-1 [4-(4-fluoro-phenyl)-piperazin-1-yl]-[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophen-2-yl]-methanone 
• 947540-87-6 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-carboxylic acid phenylamide 
• 1158984-55-4 ethyl-5-(2-(3-trifluoromethylphenyl)-pyrimidin-4-yl)-thiophene-2-carboxylate 
• 145739-67-9 C₉H₉BrO₃S 

Relevant academic research and scientific papers

Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease

Since high MAO-B levels are present in early stages of AD, the MAO-B system can be designated as an appropriate and prospective tracer target of molecular imaging biomarkers for the detection of early AD. According to the preceding investigations of Mishr

THERAPEUTIC ISOXAZOLE COMPOUNDS

The invention provides a compound of formula I: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.